Patenting perspective on Keap1 inhibitors (2019-2024)

被引：0
|
作者：
Luo, Yongfu [1 ]
Yang, Ziyu [1 ]
Zhang, Yuan [1 ]
Jiang, Shutong [1 ]
Zhu, Jingyu [1 ]
Li, Xiangyang [1 ,2 ]
You, Qidong [1 ,3 ,4 ,5 ]
Lu, Mengchen [1 ]
机构：
[1] Soochow Univ, Coll Pharmaceut Sci, Med Coll, Dept Med Chem, Suzhou 215123, Peoples R China
[2] Microcell Pharmaceut Suzhou Co Ltd, Dept Res & Dev, Suzhou, Peoples R China
[3] China Pharmaceut Univ, Jiangsu Key Lab Drug Design & Optimizat, TongJiaXiang 24, Nanjing 210009, Peoples R China
[4] China Pharmaceut Univ, State Key Lab Nat Med, TongJiaXiang 24, Nanjing 210009, Peoples R China
[5] China Pharmaceut Univ, Nanjing 211198, Peoples R China
来源：
EXPERT OPINION ON THERAPEUTIC PATENTS | 2025年 / 35卷 / 04期
基金：
中国国家自然科学基金;
关键词：
Keap1; Nrf2; oxidative stress; electrophilic inhibitors; protein-protein interaction inhibitors; PROTEIN-PROTEIN INTERACTION; FUMARIC-ACID ESTERS; OXIDATIVE STRESS; DIMETHYL FUMARATE; MULTIPLE-SCLEROSIS; KELCH DOMAIN; NRF2; PATHWAY; ACTIVATION; BINDING; REDOX;
D O I：
10.1080/13543776.2025.2462844
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
IntroductionKelch-like ECH-associated protein 1 (Keap1), an E3 ligase negatively regulating the nuclear factor erythroid 2-related factor 2 (Nrf2), has emerged as an auspicious drug target for treating ailments associated with oxidative stress and inflammation. Discovery of Keap1 inhibitors have attracted significant interest. Areas coveredThis review covers patents on Keap1 inhibitors from 2019 to 2024, providing a comprehensive analysis of their structural characteristics, optimization strategies, pharmacological properties and clinical progress. Expert opinionExtensive efforts have been devoted to enhance potency and drug-like properties of Keap1 inhibitors. Strategies such as ROS-cleavable prodrug design, bivalent inhibition and PROTACs are emerging. As the range of drug types and applications expands, Keap1 inhibitors are becoming a sagacious option for disease treating.
引用
收藏
页码：325 / 356
页数：32
相关论文
共 50 条
  • [1] Research progress on the role and inhibitors of Keap1 signaling pathway in inflammation
    Ding, Chao
    Wu, Ying
    Zhan, Chaochao
    Naseem, Anam
    Chen, Lixia
    Li, Hua
    Yang, Bingyou
    Liu, Yan
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 141
  • [2] Design and characterization of a heterobifunctional degrader of KEAP1
    Chen, Hao
    Nguyen, Nghi H.
    Magtoto, Charlene M.
    Cobbold, Simon A.
    Bidgood, Grace M.
    Guzman, Lizeth G. Meza
    Richardson, Lachlan W.
    Corbin, Jason
    Au, Amanda E.
    Lechtenberg, Bernhard C.
    Feltham, Rebecca
    Sutherland, Kate D.
    Grohmann, Christoph
    Nicholson, Sandra E.
    Sleebs, Brad E.
    REDOX BIOLOGY, 2023, 59
  • [3] Reversible Keap1 inhibitors are preferential pharmacological tools to modulate cellular mitophagy
    Georgakopoulos, Nikolaos D.
    Frison, Michele
    Alvarez, Maria Soledad
    Bertrand, Helene
    Wells, Geoff
    Campanella, Michelangelo
    SCIENTIFIC REPORTS, 2017, 7
  • [4] Keap1/Nrf2 system regulates neuronal survival as revealed through study of keap1 gene-knockout mice
    Satoh, Takumi
    Harada, Nobuhiko
    Hosoya, Tomonori
    Tohyama, Koujiro
    Yamamoto, Masayuki
    Itoh, Ken
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2009, 380 (02) : 298 - 302
  • [5] KEAP1 inhibition is neuroprotective and suppresses the development of epilepsy
    Shekh-Ahmad, Tawfeeq
    Eckel, Ramona
    Naidu, Sharadha Dayalan
    Higgins, Maureen
    Yamamoto, Masayuki
    Dinkova-Kostova, Albena T.
    Kovac, Stjepana
    Abramov, Andrey Y.
    Walker, Matthew C.
    BRAIN, 2018, 141 : 1390 - 1403
  • [6] In-silico based discovery of potential Keap1 inhibitors using the strategies of pharmacophore screening, molecular docking, and MD simulation studies
    Singh, Ekta
    Matada, Gurubasavaraja Swamy Purawarga
    Dhiwar, Prasad Sanjay
    Patil, Rajesh B.
    Pal, Rohit
    BIOIMPACTS, 2024,
  • [7] Aberrant Keap1 methylation in breast cancer and association with clinicopathological features
    Barbano, Raffaela
    Muscarella, Lucia Anna
    Pasculli, Barbara
    Valori, Vanna Maria
    Fontana, Andrea
    Coco, Michelina
    la Torre, Annamaria
    Balsamo, Teresa
    Poeta, Maria Luana
    Marangi, Giovanni Francesco
    Maiello, Evaristo
    Castelvetere, Marina
    Pellegrini, Fabio
    Murgo, Roberto
    Fazio, Vito Michele
    Parrella, Paola
    EPIGENETICS, 2013, 8 (01) : 105 - 112
  • [8] Nrf2/Keap1/ARE signaling: Towards specific regulation
    Ulasov, Alexey, V
    Rosenkranz, Andrey A.
    Georgiev, Georgii P.
    Sobolev, Alexander S.
    LIFE SCIENCES, 2022, 291
  • [9] Combined Peptide and Small-Molecule Approach toward Nonacidic THIQ Inhibitors of the KEAP1/NRF2 Interaction
    Ontoria, Jesus M.
    Biancofiore, Ilaria
    Fezzardi, Paola
    Ferrigno, Federica
    Torrente, Esther
    Colarusso, Stefania
    Bianchi, Elisabetta
    Andreini, Matteo
    Patsilinakos, Alexandros
    Kempf, Georg
    Augustin, Martin
    Steinbacher, Stefan
    Summa, Vincenzo
    Pacifici, Robert
    Munoz-Sanjuan, Ignacio
    Park, Larry
    Bresciani, Alberto
    Dominguez, Celia
    Sherman, Leticia Toledo
    Harper, Steven
    ACS MEDICINAL CHEMISTRY LETTERS, 2020, 11 (05): : 740 - 746
  • [10] Molecular recognition between potential natural inhibitors of the Keap1-Nrf2 complex
    Bello, Martiniano
    Antonio Morales-Gonzalez, Jose
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2017, 105 : 981 - 992
12345